ZTS Q2 2021 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena

ZTSZoetis Inc.

$52B

Q2 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.9B+25.8% YoY

Gross Profit

$1.3B68.7% margin

Operating Income

$724M37.2% margin

Net Income

$512M26.3% margin

EPS (Diluted)

$1.07

QoQ Revenue Growth

+4.1%

Cash Flow

Operating Cash Flow

$481M

Free Cash Flow

$368M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$14.1B

Total Liabilities

$9.7B

Stockholders' Equity

$4.3B

Cash & Equivalents

$3.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.9B	$1.5B	+25.8%
Gross Profit	$1.3B	$1.1B	+26.7%
Operating Income	$724M	$553M	+30.9%
Net Income	$512M	$377M	+35.8%

Revenue Segments

Dogs and Cats

$1.2B61%

Cattle

$342M18%

Swine

$161M8%

Poultry

$134M7%

Horses

$68M4%

Fish

$39M2%

Geographic Segments

United States Segment

$1.0B52%

International Segment

$924M48%